American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

  • About
    • Mission Statement and Purpose
    • Divisions & Services of the Society
      • Education
        • Scientific Program/Resident Courses
        • Surgical Videos
        • Journal Club
        • Journals
        • Global Outreach
        • Awards
          • Margaret F. Butler Award
      • Diversity, Equity and Inclusion Division
      • Patient Care
        • Cancer Survivorship
          • Patient Education on Post-Treatment Care
          • Interviews with Cancer Survivors
        • Cancer Prevention
          • SLIDE DECK: HPV-Related Oropharyngeal Cancer
        • Guidelines/Position Statements
        • Find-A-Physician
      • Research
        • Grant Information
        • Clinical Trial
        • Tissue Banks
      • Administrative Division
        • AHNS Process for Evaluating Projects Requiring Funding
    • Leadership
    • History
      • Society Background
      • AHNS History Interviews
      • Past Presidents
      • In Memory
    • AHNS Newsletter
    • Professionalism & Ethics
    • AHNS Policies and Procedures (P&P) Manual
    • AHNS Foundation
    • AHNS Bylaws
    • AHNS Staff
    • AHNS News and Announcements
    • COVID-19 Bulletin Board
  • Heads Up!
  • Post a Job
  • Meetings
    • AHNS Virtual Education Series
      • TORS Webinar Series
    • AHNS Meetings Info
    • AHNS Call For Abstracts
    • Past Meetings
    • Related Meetings
  • For Patients
  • For Trainees
    • Fellowship Curriculum for FY2024-2025
      • For Current AHNS Fellows
      • Certificate of Completion Request
    • Accredited Fellowships
      • Directory of Fellowships
      • AHNS Fellowship Match
      • Fellowship Curriculum
      • Fellowship Graduates
      • For Program Directors
    • AHNS Surgical Videos
    • Fellows’ Virtual Tumor Boards
    • Cutaneous Cancer
  • Sections
    • Endocrine Surgery
    • Skull Base Surgery Section
    • Reconstructive Head & Neck Surgery
      • Head and Neck Reconstruction- Information for Patients
    • Mucosal Malignancy Section
      • Mucosal Malignancy Section Patient Information
    • Salivary Gland Section
      • Salivary Gland Section Patient Education Handout: Parotidectomy
    • Cutaneous Cancer
  • Find-A-Physician
  • Member Central
    • Join AHNS
    • Find-A-Physician
    • Mailing List Order
  • Login
    • Password Reset
  • Donate

Published on September 22, 2020 by AHNS Webmaster

AHNS Virtual Education Series

Trends in Management of HPV Positive Cancers

Instructional Course: Trends in Management of HPV Positive Cancers

The AHNS gratefully acknowledges a generous educational grant of this activity from Intuitive Surgical.

Date: Wednesday, October 14, 2020

Time: 4:00 PM Pacific /6:00 PM Central / 7:00 PM Eastern
Session is an hour long

Register Here

Learning Objective:
Attendees will be able to review and discuss the role of deintensification for HPV+ cancer.

Faculty:
Carole Fakhry, MD, MPH Johns Hopkins University – Moderator
Robert Ferris, MD, PhD, University of Pittsburgh Medical Center – Speaker
Sue Yom, MD, PhD, University of California San Francisco – Speaker

Current Schedule (US Pacific Time)

4:00pm – 4:05pm – Welcome and Introduction – Carole Fakhry, MD, MPH

4:05pm – 4:20pm – Use of Transoral Surgery to Deintensify Adjuvant Therapy for p16+ Oropharynx Cancer: How results of ECOG3311 may affect clinical practice – Robert Ferris, MD, PhD

4:20pm-4:35pm – Evolutions in Radiotherapy Volumes and Dose Prescriptions – Sue Yom, MD, PhD

4:35pm – 5:00pm – Questions and Answers from Panel

The American Head and Neck Society (AHNS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

The American Head and Neck Society (AHNS) designated this live activity for a maximum of 1 AMA PRA 1 Credit(s)TM. Physicians should claim only the credit they commensurate with the extent of their participation in the activity.

Additional Information

 

Published on September 17, 2020 by AHNS Webmaster

AHNS Virtual Education Series

Instructional Course: Trends in Management of HPV Positive Cancers

The AHNS gratefully acknowledges a generous educational grant in support of this activity from Intuitive Surgical.

Date: Wednesday, October 14, 2020
Time: 4:00 PM Pacific /6:00 PM Central / 7:00 PM Eastern
Session is an hour long

Register Here

Learning Objective:
Attendees will be able to review and discuss the role of deintensification for HPV+ cancer.

Faculty:
Carole Fakhry, MD, MPH Johns Hopkins University – Moderator
Robert Ferris, MD, PhD, University of Pittsburgh Medical Center – Speaker
Sue Yom, MD, PhD, University of California San Francisco – Speaker

 

Published on September 16, 2020 by AHNS Webmaster

Congratulations on a great Twitter chat!

On September 10th, 2020 the AHNS Endocrine Section and ThyCa teamed up for the latest Twitter Chat, in celebration of September as Thyroid Cancer Awareness Month.  The topic focused on “Recurrent Thyroid Cancer” and focused on differences in surgical approach, ethanol ablation, radiofrequency ablation, and active surveillance.  The chat was an amazing success – surgeons and endocrinologists fielded questions and learned from the perspectives of thyroid cancer survivors. There were more than 450 tweets for 1.3 million Impressions!

AHNS Endocrine Section members who participated included Carol Bier-Laning, Amy Chen, Vinny Dhillon, Allen Ho, Daniel Kwon, Caitlin McMullen, Greg Randolph, Jonathan Russell, Merry Sebelik, Catherine Sinclair, Brendan Stack, and James Wu.

Published on September 15, 2020 by Theresa Guo

AHNS Basic Science/Translational Newsletter Vol 4 – American Head & Neck Society

Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

Carole Fakhry, Amanda L Blackford, Geoff Neuner, Weihong Xiao, Bo Jiang, Amit Agrawal, Maura L Gillison

From JAMA Oncology, July 2019; 5(7):985-992.

Article Review by Theresa Guo, MD

Background / Hypothesis
Recent retrospective studies have shown that detection of HPV-16 DNA in oral rinse of HPV+ oropharyngeal cancer patients may predict increased risk for
recurrence. Therefore, a prospective study was designed to evaluate whether detection of HPV
DNA in oral rinses was able to predict clinical disease course.

Design
Multi-institutional prospective study enrolling patients diagnosed with oropharyngeal or oral cavity cancer. Oral rinses were collected at the time of diagnosis, after primary therapy, weekly during radiotherapy and at the completion of therapy. Rinses were tested for DNA of 37 HPV types by PCR.

Summary of Results
396 patients were enrolled including 217 oropharyngeal and 170 oral cavity patients, with 202 HPV-positive and 194 HPV-negative patients. At the time of diagnosis, oral HPV-16 DNA was 81% sensitive and 100% sensitive for HPV-16 positive tumors, and higher T stage was associated with oral HPV detection. In HPV-negative patients, oral HPV DNA was detected in 12.4% of patients. During treatment, tumor specific HPV type or “tumor-type HPV” decreased significantly during treatment, but non tumor-type HPV did not change. Tumor-type HPV was present in 14.3% of HPV-positive patients after completion of primary therapy, and recurrence rates were significantly higher than those without detectable DNA (45.3% vs. 12.2%). Persistent tumor-type DNA in oral rinses was significantly associated with increased risk of death (adjusted HR 6.61, p=0.003) as well as local (adjusted HR 9.81, p<0.001) and regional (adjusted HR 5.75, p=0.002) recurrence, but not distant recurrence.

Strengths

  • Large prospectively collected cohort including nearly 400 patients with half of the
    cohort being HPV-positive and half being HPV-negative, including both oral cavity and
    oropharynx primary tumors (which are most likely to shed DNA into saliva).
  • Rigorous testing of 37 HPV subtypes within tumor as well as saliva samples.
  • Robust data on dynamics of tumor-type HPV DNA throughout treatment including
    before and after surgery, as well as weekly during radiation treatment.

 Weaknesses

  • Lack data on plasma sampling to supplement oral rinses. The authors found that while
    oral rinse HPV DNA could predict locoregional recurrence, it was not associated with
    distant recurrence. Predicting distant recurrence may require plasma sampling for
    detection.
  • Follow up time was limited to a median of 2.6 years. While most recurrences in
    oropharyngeal cancer occur within 2 years, some data has shown late recurrences from HPV-positive tumors. The authors hypothesize that persistent HPV DNA likely represents subclinical disease that results in recurrence, thus it is unknown whether persistent HPV infection would be able to predict late recurrences.

Key Points

  • Oral HPV is detectable in 80% of patients with HPV-positive oropharyngeal cancer at the time of diagnosis.
  • Unlike EBV viral load in nasopharyngeal cancer, viral load or presence of HPV DNA at the time of diagnosis was not associated with clinical outcomes.
  • Detection of HPV is complicated by prevalence of non-tumor related HPV infections. This study highlights some of the nuances of using oral HPV as a surveillance biomarker, as only tumor-type HPV reflected the clinical disease course. There were no changes during treatment for viral load of non-tumor-type HPV. Furthermore, HPV-negative patients also demonstrated 12.4% prevalence of HPV DNA, and risk of infection in these patients was associated with the same risk factors for HPV infection in the general population, including male sex and number of lifetime sexual partners.
  • Active smoking was associated with persistent tumor-type DNA.
  • Persistent tumor-type HPV DNA is associated with both worse survival and locoregional recurrence. Future trial designs may consider additional therapy such as immunotherapy for patients with persistent HPV DNA after treatment completion.

From the Basic Science/Translational Service
Jeffrey C. Liu MD Vice Chair
Richard Wong MD Chair

  • Bio
  • Latest Posts
Theresa Guo

Theresa Guo

I am from Cleveland, Ohio where I received my medical degree from the Cleveland Clinic Lerner College of Medicine. I completed my Otolaryngology residency training at Johns Hopkins Hospital, and will be pursuing advanced fellowship training in Head & Neck Cancer at MD Anderson in Houston, Texas. My clinical and research interests are in advancing the treatment of head and neck cancer. In particular, I am interested in genetic profiling of head and neck tumors with poor prognosis and predicting treatment response.
Theresa Guo

Latest posts by Theresa Guo (see all)

  • AHNS Basic Science/Translational Newsletter Vol 4 – American Head & Neck Society - September 15, 2020

Published on September 11, 2020 by AHNS Webmaster

AHNS 2020 Myers Family Summer Diversity Travel Fellowship

Congratulations to AHNS 2020 Awardee!

Mr. Derrick Lewis. A second-year medical student at Mayo Clinic Alix School of Medicine, Derrick Lewis has consistently supported some of the most vulnerable communities in the greater Boston area.

Mr. Lewis is a medical student with early interest in otolaryngology-head and neck surgery in part due to his experience as a paramedic.

An excerpt from his application personal statement reads as follows:

“As a paramedic, I led my crew within a well-defined scope of practice. But I wanted to do more…So, I decided to attend medical school. And now that I’m here, I’ve learned that the disparities I observed extend far beyond Boston, far beyond emergency medicine, and even extend into the realm of otorhinolaryngology, head and neck surgery…I want to learn more about head and neck surgery while participating in research that will enhance the field and the practice of medicine more generally. This fellowship will allow me to engage in that work unencumbered by finances and provide me with the mentorship and networking I need to be productive and competitive come residency application season.”

 

 

  • « Previous Page
  • 1
  • …
  • 54
  • 55
  • 56
  • 57
  • 58
  • …
  • 68
  • Next Page »

News and Announcements

  • AHNS YMCP Episode 11 – Melina Windon, MD, Janice Farlow, MD, Eric Gantwerker, MD May 8, 2025
  • Artificial Intelligence in Management of H&N Cancer: New Horizons Presented April 28, 2025
  • A conversation with Dr. Uppaluri: Neoadjuvant Therapy for Advanced H&N Mucosal April 25, 2025
  • The End of April Head and Neck Cancer Awareness Month Approaches! April 23, 2025
  • April is National CBD Awareness Month! April 21, 2025

AHNS Meetings and Events

AHNS 2025 Annual Meeting
Held during the Combined Otolaryngology Spring Meetings (COSM)

May 14-18, 2025
Hyatt Regency New Orleans
New Orleans, Louisiana

learn more...

Contact Us

AHNS, 11300 W. Olympic Blvd, Suite 600
Los Angeles, CA 90064
ph: (310) 437-0559 / fx: (310) 437-0585
[email protected]

Welcome to the AHNS Virtual Repository of Scientific Research

Sections

  • Virtual Repository of Scientific Resources
  • Cell Lines Browse and Search
  • Omics Browse and Search
  • Patient Derived Xenografts Browse and Search
  • Plasmids Browse and Search
  • Pre-Clinical Models Browse and Search
  • Transferable Expertise Browse and Search
  • Transgenic Mice Browse and Search

© 2002–2025 American Head and Neck Society · Privacy and Return Policy
· Managed by BSC Management, Inc